22 Grants
2021
Experimental and Developmental Therapeutics Program
BOOTHMAN, DAVID A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5P30CA082709-22-5167), $31,801USD, 1999-09-22 -- 2024-08-31
2020
Experimental and Developmental Therapeutics Program
BOOTHMAN, DAVID A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5P30CA082709-21-5167), $31,801USD, 1999-09-22 -- 2024-08-31
 
Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer
BOOTHMAN, DAVID A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA221158-04), $344,771USD, 2017-06-07 -- 2022-11-30
2019
Experimental and Developmental Therapeutics Program
BOOTHMAN, DAVID A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 2P30CA082709-20-5167), $31,801USD, 2019
 
Model-based Prediction of Redox-Modulated Responses to Cancer Treatments
BOOTHMAN, DAVID A⋅Furdui, Cristina M and KEMP, MELISSA L
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5U01CA215848-03), $705,961USD, 09/04/2017 -- 08/31/2022
 
RPRD1B/Kub5/Hera, an RNA Pol II determinant that controls PARPi & IR sensitivity
BOOTHMAN, DAVID A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA210489-05), $349,472USD, 07/05/2016 -- 06/30/2021
 
Tumor-selective radiosensitization of NSCLC using NQO1 bioactivatable drugs
BOOTHMAN, DAVID A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA224493-02), $349,472USD, 01/10/2018 -- 12/31/2022
 
Tumor-selective use of PARP inhibitors against NQO1+ nonsmall cell lung cancer
BOOTHMAN, DAVID A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA221158-03), $373,368USD, 06/07/2017 -- 11/30/2022
2018
Model-based Prediction of Redox-Modulated Responses to Cancer Treatments
BOOTHMAN, DAVID A⋅Furdui, Cristina M and KEMP, MELISSA L
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5U01CA215848-02), $825,581USD, 09/04/2017 -- 08/31/2022
 
RPRD1B/Kub5/Hera, an RNA Pol II determinant that controls PARPi & IR sensitivity
BOOTHMAN, DAVID A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA210489-04), $360,281USD, 07/05/2016 -- 06/30/2021
 
Tumor-selective radiosensitization of NSCLC using NQO1 bioactivatable drugs
BOOTHMAN, DAVID A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA224493-01), $347,128USD, 01/10/2018 -- 12/31/2022
2017
Model-based Prediction of Redox-Modulated Responses to Cancer Treatments
BOOTHMAN, DAVID A⋅Furdui, Cristina M and KEMP, MELISSA L
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1U01CA215848-01A1), $657,611USD, 09/04/2017 -- 08/31/2022
 
RPRD1B/Kub5/Hera, an RNA Pol II determinant that controls PARPi & IR sensitivity
BOOTHMAN, DAVID A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA210489-02), $55,695USD, 07/05/2016 -- 11/15/2017
 
RPRD1B/Kub5/Hera, an RNA Pol II determinant that controls PARPi & IR sensitivity
BOOTHMAN, DAVID A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 7R01CA210489-03), $314,880USD, 07/05/2016 -- 06/30/2021
2016
RPRD1B/Kub5/Hera, an RNA Pol II determinant that controls PARPi & IR sensitivity
BOOTHMAN, DAVID A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA210489-01), $369,527USD, 07/05/2016 -- 06/30/2021
2014
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
BOOTHMAN, DAVID A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA139217-05), $310,426USD, 07/01/2010 -- 04/30/2015
 
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
BOOTHMAN, DAVID A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R01CA139217-05S1), $93,209USD, 07/01/2010 -- 04/30/2015
2013
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
BOOTHMAN, DAVID A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA139217-04), $300,826USD, 07/01/2010 -- 04/30/2015
 
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
BOOTHMAN, DAVID A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 3R01CA139217-04S1), $74,450USD, 07/01/2010 -- 04/30/2015
2012
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
BOOTHMAN, DAVID A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA139217-03), $319,692USD, 07/01/2010 -- 04/30/2015
2011
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
BOOTHMAN, DAVID A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R01CA139217-02), $319,021USD, 07/01/2010 -- 04/30/2015
2010
Ku70 Binding Protein-5 (KUB5), a Novel Factor in Nonhomologous End Joining
BOOTHMAN, DAVID A
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R01CA139217-01A2), $328,888USD, 07/01/2010 -- 04/30/2015